Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Myrin 2 · 1 trial · 1 indication
AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | Test |
| B | ACTIVE_COMPARATOR | Reference |
| Name | Type | Description |
|---|---|---|
| Myrin© 2 (Rifampicin + Isoniazid) | DRUG | Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg |
| Rimactane® (Rifampicin) | DRUG | One (1) capsule of Rifampicin 300 mg |
Inclusion Criteria: * Healthy male subjects between the ages of 18 and 55 years, inclusive. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). * An informed consent document signed and dated by the subject. * Subjects willing and able to comply with scheduled ...
Top 2 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT164a1, BNT164b1 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | Ganfeborole |
Myrin 2 is a fixed-dose combination of rifampicin and isoniazid developed for the treatment of tuberculosis. It is a small-molecule anti-infective product. The only clinical study of Myrin 2 on record was a Phase 1 bioequivalence study conducted in healthy adult male volunteers in the Philippines.
Myrin 2 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor associated with the fixed-dose combination product containing rifampicin and isoniazid.
Myrin 2 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The completed study was an active-controlled, randomized bioequivalence study, and it was not double blinded. Myrin 2 is investigational and is not described as approved.
Myrin 2 has been studied in one completed Phase 1 trial, NCT01311505. That trial was a bioequivalence study comparing the rifampicin component in the fixed-dose combination Myrin 2 with the reference drug Rimactane, a stand-alone rifampicin product. It enrolled 21 healthy adult male volunteers in the Philippines.